MiR-150 Functions As a Tumour Suppressor in Human Colorectal Cancer by Targeting C-Myb

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2014 Sep 19

PMID 25230975

Citations 48

Authors

Junlan Feng

Yongzhi Yang

Peng Zhang

Feng Wang

Yanlei Ma

Huanlong Qin

Yu Wang

Affiliations

Soon will be listed here.

Abstract

Our previously published study documented a deregulation of the microRNA miR-150 in colorectal cancer. Here, we investigated further, in vitro and in vivo, the potential molecular mechanisms underlying the involvement of miR-150 in colorectal cancer, using the appropriate molecular biological methods. We report that miR-150 is a key regulator in the tumourigenesis and progression of colorectal cancer, by acting as a tumour suppressor targeting c-Myb. The current findings suggest that miR-150 may have important roles in the pathogenesis of colorectal cancer.

Citing Articles

Unsaturated Fatty Acid Synthesis Is Associated with Worse Survival and Is Differentially Regulated by and Tumor Suppressor microRNAs in Neuroblastoma.

Sheeter D, Garza S, Park H, Benhamou L, Badi N, Espinosa E Cancers (Basel). 2024; 16(8).

PMID: 38672672 PMC: 11048984. DOI: 10.3390/cancers16081590.

Molecular detection of exosomal miRNAs of blood serum for prognosis of colorectal cancer.

Bakhsh T, Alhazmi S, Farsi A, Yusuf A, Alharthi A, Qahl S Sci Rep. 2024; 14(1):8902.

PMID: 38632250 PMC: 11024162. DOI: 10.1038/s41598-024-58536-3.

Integrated whole transcriptome profiling revealed a convoluted circular RNA-based competing endogenous RNAs regulatory network in colorectal cancer.

Mollanoori H, Ghelmani Y, Hassani B, Dehghani M Sci Rep. 2024; 14(1):91.

PMID: 38167453 PMC: 10761719. DOI: 10.1038/s41598-023-50230-0.

Therapeutic potential of natural antisense transcripts and various mechanisms involved for clinical applications and disease prevention.

Ali A, Khatoon A, Shao C, Murtaza B, Tanveer Q, Su Z RNA Biol. 2023; 21(1):1-18.

PMID: 38090817 PMC: 10761088. DOI: 10.1080/15476286.2023.2293335.

Corrigendum.

J Cell Mol Med. 2022; 26(18):4872.

PMID: 36089799 PMC: 9465181. DOI: 10.1111/jcmm.17503.

References

Lin Y, Kuo M, Yu J, Kuo H, Lin R, Lo W . c-Myb is an evolutionary conserved miR-150 target and miR-150/c-Myb interaction is important for embryonic development. Mol Biol Evol. 2008; 25(10):2189-98. DOI: 10.1093/molbev/msn165. View

Oh I, Reddy E . The myb gene family in cell growth, differentiation and apoptosis. Oncogene. 1999; 18(19):3017-33. DOI: 10.1038/sj.onc.1202839. View

Tomita A, Watanabe T, Kosugi H, Ohashi H, Uchida T, Kinoshita T . Truncated c-Myb expression in the human leukemia cell line TK-6. Leukemia. 1998; 12(9):1422-9. DOI: 10.1038/sj.leu.2401113. View

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

Weitz J, Koch M, Debus J, Hohler T, Galle P, Buchler M . Colorectal cancer. Lancet. 2005; 365(9454):153-65. DOI: 10.1016/S0140-6736(05)17706-X. View

He L, Hannon G . MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522-31. DOI: 10.1038/nrg1379. View

Ma Y, Zhang P, Wang F, Zhang H, Yang J, Peng J . miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2011; 61(10):1447-53. DOI: 10.1136/gutjnl-2011-301122. View

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351(4):337-45. DOI: 10.1056/NEJMoa033025. View

Lutwyche J, Keough R, Hughes T, Gonda T . Mutation screening of the c-MYB negative regulatory domain in acute and chronic myeloid leukaemia. Br J Haematol. 2001; 114(3):632-4. DOI: 10.1046/j.1365-2141.2001.02966.x. View

10.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

11.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M . Cancer statistics, 2007. CA Cancer J Clin. 2007; 57(1):43-66. DOI: 10.3322/canjclin.57.1.43. View

12.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G . Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11(8):753-62. DOI: 10.1016/S1470-2045(10)70130-3. View

13.

Tesch H, Michels M, Jucker M, Pahl I, Klein S, Bading H . Heterogeneous expression of c-myb protein in human leukemia detected by simultaneous two color flow cytometric analysis. Leuk Res. 1992; 16(3):265-74. DOI: 10.1016/0145-2126(92)90064-e. View

14.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

15.

Esquela-Kerscher A, Slack F . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69. DOI: 10.1038/nrc1840. View

16.

Pelicci P, Lanfrancone L, Brathwaite M, WOLMAN S, Dalla-Favera R . Amplification of the c-myb oncogene in a case of human acute myelogenous leukemia. Science. 1984; 224(4653):1117-21. DOI: 10.1126/science.6585957. View

17.

Lu J, Getz G, Miska E, Alvarez-Saavedra E, Lamb J, Peck D . MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8. DOI: 10.1038/nature03702. View

18.

Bartel D . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-33. PMC: 3794896. DOI: 10.1016/j.cell.2009.01.002. View

19.

Calin G, Dumitru C, Shimizu M, Bichi R, Zupo S, Noch E . Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99(24):15524-9. PMC: 137750. DOI: 10.1073/pnas.242606799. View

20.

Biroccio A, Benassi B, DAgnano I, DAngelo C, Buglioni S, Mottolese M . c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol. 2001; 158(4):1289-99. PMC: 1891926. DOI: 10.1016/S0002-9440(10)64080-1. View